Canada Prepares Health System for Type 1 Diabetes Cell Therapies

Type 1 diabetes cell therapies represent a different approach to managing the disease. Rather than managing blood sugar levels, these treatments aim to restore the body's own insulin production by replacing beta cells that have been destroyed by the immune system.

Many cell therapies in development use stem cells as a starting point, sometimes with genetic modifications to improve their function and longevity. This approach differs significantly from traditional medications or devices, which has implications for how they must be approved, funded, and delivered to patients.

Cell therapies for type 1 diabetes are not simple pills or injections. Most require surgical implantation and must be delivered at well-equipped medical centers by trained healthcare teams. This complexity extends beyond the lab—it affects how regulators approve them, how health systems pay for them, and where and how patients can receive them.

Canada's existing systems for drug approval, reimbursement, and healthcare delivery were designed for traditional treatments. Experts recognize that these systems may need to adapt to support the unique demands of cell therapies.

In June 2025, Breakthrough T1D Canada, the Stem Cell Network, and Shift Health brought together more than 30 stakeholders for a two-day workshop. Participants included researchers, clinicians, biomanufacturing experts, people living with type 1 diabetes, industry representatives, government officials from Health Canada, and members of the Canadian Drug Agency.

The goal was clear: identify the barriers to cell therapy access and develop practical solutions before these treatments receive regulatory approval. By convening diverse voices—from those developing the therapies to those who will receive them—organizers aimed to ensure Canada's health system is ready for this next generation of treatment.

Clinical trials are producing increasingly promising results, suggesting that cell therapies could offer transformative benefits for people with type 1 diabetes. The timing is urgent: as the first therapies approach regulatory approval, the decisions made now about approval pathways, funding models, and delivery infrastructure will shape whether and how quickly Canadians can access these treatments.

Origin: breakthrought1d.ca (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.